Pharmas impacted by ‘minoxidil’ bioequivalence test result
By Lee, Hye-Kyung | translator Kim, Jung-Ju
24.03.06 12:05:05
가나다라
0
Union Korea Pharm makes a second attempt at bioequivalence testing after voluntary withdrawal of a drug
Dongkwang Pharm has completed the submission of bioequivalence test reports for Minoxidil
▲The bioequivalence re-evaluation of the active ingredient ‘minoxidil’ in comparison to Hyundai Pharm’s
Bioequivalence test outcomes result in different paths for prescription drugs containing the active ingredient ‘minoxidil,’ which was first introduced as a hypertension drug but is now commonly used as a hair-loss drug.
The Ministry of Food and Drug Safety (MFDS) recently issued a two-month sales suspension order on Binex’s ‘Bimo Tab 5mg.’
Binex received a notice for ‘Failing to submit the required documents for the 2023 bioequivalence re-evaluation of medicines.’ As a result, the company is banned from selling the item in question from March 11th to May 10th.
Although Bimo Tab received a drug suspension settlement, Binex continues attempting bioequivalence
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)